Trials / Active Not Recruiting
Active Not RecruitingNCT06381141
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Cullinan Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CLN-619 | Anti-MICA/MICB monoclonal antibody |
Timeline
- Start date
- 2024-09-03
- Primary completion
- 2026-09-01
- Completion
- 2027-03-01
- First posted
- 2024-04-24
- Last updated
- 2025-09-18
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06381141. Inclusion in this directory is not an endorsement.